-
Patent Agency Ranking
公开(公告)号：US20130210818A1
公开(公告)日：2013-08-15
申请号：US13396339
申请日：2012-02-14
Applicant: Zilin Huang , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
Inventor： Zilin Huang , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
IPC: A61K31/444 , A61K31/506 , C07D403/14 , C07D405/14 , A61K31/4439 , C07D417/14 , C07D471/04 , C07D413/14 , A61K31/496 , C07D487/04 , A61K31/4985 , C07D498/04 , A61K31/5383 , A61K31/4709 , A61K31/5377 , A61P35/00 , C07D401/14
CPC classification number: A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/5383 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/04 , A61K2300/00
Abstract: New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
Abstract translation: 提供了新的取代的杂环化合物，含有它们的组合物，以及使用它们来抑制Raf激酶活性的方法。 新化合物和组合物可以单独使用或与至少一种另外的药物组合使用，用于治疗Raf激酶介导的病症，例如癌症。
-
公开(公告)号：US20100003246A1
公开(公告)日：2010-01-07
申请号：US12383035
申请日：2009-03-19
Applicant: Zilin Hunag , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
Inventor： Zilin Hunag , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
IPC: A61K31/444 , C07D401/14 , C07D403/14 , C07D471/04 , A61K31/506 , A61K31/437 , A61P35/00 , A61K31/4545 , A61K31/7068 , A61K31/505 , A61K33/24 , A61K39/395
CPC classification number: C07D498/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
Abstract translation: 提供了新的取代的杂环化合物，含有它们的组合物，以及使用它们来抑制Raf激酶活性的方法。 新化合物和组合物可以单独使用或与至少一种另外的药物组合使用，用于治疗Raf激酶介导的病症，例如癌症。
-
公开(公告)号：US09207302B2
公开(公告)日：2015-12-08
申请号：US13980538
申请日：2011-11-28
Applicant: Xueming Jiang , Jiong Zhu , Yan Zhang , Jinjuan Huang , Li Yao , Tao Xiao , Yongjin Xu , Feng Xie
Inventor： Xueming Jiang , Jiong Zhu , Yan Zhang , Jinjuan Huang , Li Yao , Tao Xiao , Yongjin Xu , Feng Xie
Abstract: A fully-automatic verification system for intelligent electric energy meters comprises a plurality of verification units for automatic verification of the electric energy meters, main transport lines for connecting the verification units, and a verification management system for coordinating the work of the verification units. The main transport lines comprise upper transport lines for transporting boxes carrying electric energy meters to be verified to the verification units and lower transport lines for transporting the boxes carrying the electric energy meters back to the warehouse. The verification system for electric energy meters can implement fully-automatic verification, thus enhancing the efficiency and the verification accuracy.
Abstract translation: 智能电能表全自动验证系统包括多个用于电能表自动验证的验证单元，用于连接验证单元的主输送线，以及用于协调验证单元工作的验证管理系统。 主要运输线路包括用于运送携带电能表的箱子的上部运输线路，以验证验证单元和用于将携带电能表的箱子运送回仓库的下部运输线路。 电能表验证系统可以实现全自动验证，提高效率和验证精度。
-
公开(公告)号：US08865732B2
公开(公告)日：2014-10-21
申请号：US13396339
申请日：2012-02-14
Applicant: Zilin Huang , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
Inventor： Zilin Huang , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
IPC: A61K31/505 , C07D241/02
CPC classification number: A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/5383 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/04 , A61K2300/00
Abstract: New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
Abstract translation: 提供了新的取代的杂环化合物，含有它们的组合物，以及使用它们来抑制Raf激酶活性的方法。 新化合物和组合物可以单独使用或与至少一种另外的药物组合使用，用于治疗Raf激酶介导的病症，例如癌症。
-
公开(公告)号：US08129394B2
公开(公告)日：2012-03-06
申请号：US12383035
申请日：2009-03-19
Applicant: Zilin Hunag , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
Inventor： Zilin Hunag , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
IPC: A61K31/4965 , A61K31/505 , A01N43/54 , C07D403/00 , C07D401/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00
CPC classification number: C07D498/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: Novel imidazole compounds of the general formula are disclosed, wherein R1 and R2 comprise heteroaryl groups. These compounds and compositions containing them are useful in methods to treat Raf kinase-mediated disorders such as cancer.
Abstract translation: 公开了通式的新型咪唑化合物，其中R 1和R 2包含杂芳基。 这些含有它们的化合物和组合物可用于治疗Raf激酶介导的疾病如癌症的方法。
-
-
-
-
Search Results
5
records
(took 0.016 seconds)
